Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD
NL-OMON38572Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Umeclidinium/vilanterol with Fluticasone propionate/salmeterol (2 arms). Primary endpoint: 24-hour weighted-mean FEV1 on Treatment Day 84. Started Mar 2013; status: active, not recruiting.
02
Drugs
umeclidiniumvilanterolfluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38572.